Biotherapeutic Delivery Discovery

We have sucessfully developed orally available and BBB crossing forms of cyclotides attached to over 20 different targets. We have demonstrated a dose related plasma concentration of GI administered cyclotide/target conjugates.

Further studies have again shown BBB delivery and presence of conjugates in homogenates 24 hours after administration.

Included within the Cyclogenix portfolio are a number of specific anti-cancer projects, other targets of interest include tyrosine kinase linked receptors, cytokines, and proteases.